RSS feed

Publications (original articles or review articles) published in 2022 from OUS - Cell Signaling and Immune Regulation (Kjetil Taskén)

10 publications found

Aronson JH, Skånland SS, Roeker LE, Thompson MC, Mato AR (2022)
Approach to a patient with "double refractory" chronic lymphocytic leukemia: "Double, double toil and trouble" (Shakespeare)
Am J Hematol, 97 Suppl 2, S19-S25
DOI 10.1002/ajh.26682, PubMed 36125036

Athanasiadis P, Ianevski A, Skånland SS, Aittokallio T (2022)
Computational Pipeline for Rational Drug Combination Screening in Patient-Derived Cells
Methods Mol Biol, 2449, 327-348
DOI 10.1007/978-1-0716-2095-3_14, PubMed 35507270

Flobak Å, Skånland SS, Hovig E, Taskén K, Russnes HG (2022)
Functional precision cancer medicine: drug sensitivity screening enabled by cell culture models
Trends Pharmacol Sci, 43 (11), 973-985
DOI 10.1016/j.tips.2022.08.009, PubMed 36163057

Giliberto M, Santana LM, Holien T, Misund K, Nakken S, Vodak D, Hovig E, Meza-Zepeda LA, Coward E, Waage A, Taskén K, Skånland SS (2022)
Mutational analysis and protein profiling predict drug sensitivity in multiple myeloma cell lines
Front Oncol, 12, 1040730
DOI 10.3389/fonc.2022.1040730, PubMed 36523963

Giliberto M, Thimiri Govinda Raj DB, Cremaschi A, Skånland SS, Gade A, Tjønnfjord GE, Schjesvold F, Munthe LA, Taskén K (2022)
Ex vivo drug sensitivity screening in multiple myeloma identifies drug combinations that act synergistically
Mol Oncol, 16 (6), 1241-1258
DOI 10.1002/1878-0261.13191, PubMed 35148457

Imbery JF, Heinzelbecker J, Jebsen JK, McGowan M, Myklebust C, Bottini N, Stanford SM, Skånland SS, Tveita A, Tjønnfjord GE, Munthe LA, Szodoray P, Nakken B (2022)
T-helper cell regulation of CD45 phosphatase activity by galectin-1 and CD43 governs chronic lymphocytic leukaemia proliferation
Br J Haematol, 198 (3), 556-573
DOI 10.1111/bjh.18285, PubMed 35655388

Skånland SS, Inngjerdingen M, Bendiksen H, York J, Spetalen S, Munthe LA, Tjønnfjord GE (2022)
Functional testing of relapsed chronic lymphocytic leukemia guides precision medicine and maps response and resistance mechanisms. An index case
Haematologica, 107 (8), 1994-1998
DOI 10.3324/haematol.2021.280393, PubMed 35236056

Skånland SS, Tjønnfjord GE (2022)
Determining drug dose in the era of targeted therapies: playing it (un)safe?
Blood Cancer J, 12 (8), 123
DOI 10.1038/s41408-022-00720-7, PubMed 35999205

Wei Q, Taskén K (2022)
Immunoregulatory signal networks and tumor immune evasion mechanisms: insights into therapeutic targets and agents in clinical development
Biochem J, 479 (20), 2219-2260
DOI 10.1042/BCJ20210233, PubMed 36305711

Yin Y, Athanasiadis P, Karlsen L, Urban A, Xu H, Murali I, Fernandes SM, Arribas AJ, Hilli AK, Taskén K, Bertoni F, Mato AR, Normant E, Brown JR, Tjønnfjord GE, Aittokallio T, Skånland SS (2022)
Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic Leukemia
Clin Cancer Res, 28 (20), 4444-4455
DOI 10.1158/1078-0432.CCR-22-1221, PubMed 35998013